1
|
Yu D, Li Z, Cao J, Wei G, Shen F. LSD1 knockdown confers protection against osteoclast formation by reducing histone 3 lysine 9 monomethylation and dimethylation in ITGB3 promoter. Acta Histochem 2023; 125:152073. [PMID: 37422927 DOI: 10.1016/j.acthis.2023.152073] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2023] [Revised: 06/09/2023] [Accepted: 06/25/2023] [Indexed: 07/11/2023]
Abstract
ITGB3, an osteoclast marker, is involved in osteoclast formation. Nevertheless, its related mechanism remains poorly characterized. Herein, this study examines the mechanisms affecting osteoclast formation with the involvement of ITGB3. Osteoclast formation was induced with macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor-kappa B ligand (RANKL), followed by measurement of the mRNA and protein expression of ITGB3 and LSD1. After gain- and loss-of-function assays, cell viability and the expression of osteoclast marker genes (NFATc1, ACP5, and CTSK) were assessed, and osteoclast formation was evaluated with TRAP staining. ChIP assays were used to examine histone 3 lysine 9 (H3K9) monomethylation (H3K9me1) and H3K9 dimethylation (H3K9me2) modifications and LSD1 protein enrichment in the ITGB3 promoter. During osteoclast formation, ITGB3 and LSD1 were gradually augmented. Knockdown of LSD1 or ITGB3 curbed cell viability, the expression of osteoclast marker genes, and osteoclast formation. Moreover, overexpression of ITGB3 nullified the suppressive impact of LSD1 knockdown on osteoclast formation. Mechanistically, LSD1 promoted ITGB3 expression by reducing H3K9 levels in the ITGB3 promoter. LSD1 enhanced ITGB3 expression by decreasing H3K9me1 and H3K9me2 levels in ITGB3 promoter to boost osteoclast formation.
Collapse
Affiliation(s)
- Dongping Yu
- Department of Orthopedics, the First Hospital of Nanchang, Nanchang, Jiangxi 330008, PR China
| | - Zhen Li
- Department of Pathology, the First Hospital of Changsha, Changsha, Hunan 410005, PR China
| | - Jie Cao
- Department of Digestive, the First Hospital of Nanchang, Nanchang, Jiangxi 330008, PR China
| | - Guowen Wei
- Department of Orthopedics, the First Hospital of Nanchang, Nanchang, Jiangxi 330008, PR China
| | - Feng Shen
- Department of Orthopedics, the First Hospital of Nanchang, Nanchang, Jiangxi 330008, PR China.
| |
Collapse
|
2
|
Galang JN, Shen Y, Koitzsch U, Yu X, Eischeid-Scholz H, Bachurski D, Rau TT, Neppl C, Herling M, Bulimaga B, Vasyutina E, Schweiger MR, Büttner R, Odenthal M, Anokhina MM. Vesicular Release and Uptake of Circular LSD1-RNAs from Non-Cancer and Cancer Lung Cells. Int J Mol Sci 2023; 24:13981. [PMID: 37762282 PMCID: PMC10530930 DOI: 10.3390/ijms241813981] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2023] [Revised: 09/03/2023] [Accepted: 09/07/2023] [Indexed: 09/29/2023] Open
Abstract
Lysine-specific demethylase 1 (LSD1) is highly expressed in many cancer types and strongly associated with cancer progression and metastasis. Circular RNAs (circRNAs) are produced by back-splicing and influence the interactive RNA network by microRNA and protein sponging. In the present study, we aimedto identify circRNAs that derive from the LSD1-encoding KDM1A gene, and to investigate their potential to be released and uptaken by lung cancer versus non-cancer epithelial cells. We identified four circLSD1-RNAs by RT-PCR with divergent primers, followed by sequencing. The expression level of circLSD1-RNAs was then studied by quantitative PCR on cellular and extracellular fractions of lung cancer (PC9) and non-cancer primary small airway epithelial (PSAE) cells. Moreover, we established the transgenic overexpression of circLSD1-RNAs. We show that circLSD1-RNAs are primarily located in the cytoplasm, but are packaged and released from lung cancer and non-cancer cells by extracellular vesicles (EVs) and ribonucleoprotein (RNP) complexes, respectively. Proteomics demonstrated a different protein pattern of EV fractions released from PC9 versus PSAE cells. Importantly, released circLSD1-RNAs were differently taken up by PSAE and PC9 cells. In conclusion, our findings provide primary evidence that circLSD1-RNAs participate in the intercellular communication of lung cancer cells with the tumor environment.
Collapse
Affiliation(s)
- Joelle Noriko Galang
- Institute of Pathology, University Hospital of Cologne, 50937 Cologne, Germany; (J.N.G.); (Y.S.); (X.Y.); (H.E.-S.); (B.B.); (R.B.)
- Center for Molecular Medicine Cologne, University of Cologne, 50937 Cologne, Germany;
| | - Yefeng Shen
- Institute of Pathology, University Hospital of Cologne, 50937 Cologne, Germany; (J.N.G.); (Y.S.); (X.Y.); (H.E.-S.); (B.B.); (R.B.)
- Center for Molecular Medicine Cologne, University of Cologne, 50937 Cologne, Germany;
| | - Ulrike Koitzsch
- Institute of Pathology, University Hospital of Cologne, 50937 Cologne, Germany; (J.N.G.); (Y.S.); (X.Y.); (H.E.-S.); (B.B.); (R.B.)
- Center for Molecular Medicine Cologne, University of Cologne, 50937 Cologne, Germany;
| | - Xiaojie Yu
- Institute of Pathology, University Hospital of Cologne, 50937 Cologne, Germany; (J.N.G.); (Y.S.); (X.Y.); (H.E.-S.); (B.B.); (R.B.)
- Center for Molecular Medicine Cologne, University of Cologne, 50937 Cologne, Germany;
| | - Hannah Eischeid-Scholz
- Institute of Pathology, University Hospital of Cologne, 50937 Cologne, Germany; (J.N.G.); (Y.S.); (X.Y.); (H.E.-S.); (B.B.); (R.B.)
- Center for Molecular Medicine Cologne, University of Cologne, 50937 Cologne, Germany;
| | - Daniel Bachurski
- CECAD Center of Excellence on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, 50937 Cologne, Germany;
- Department I of Internal Medicine, University Hospital of Cologne, 50937 Cologne, Germany; (M.H.)
| | - Tilman T. Rau
- Institute of Pathology, University Hospital of Duesseldorf, 40225 Duesseldorf, Germany; (T.T.R.); (C.N.)
| | - Christina Neppl
- Institute of Pathology, University Hospital of Duesseldorf, 40225 Duesseldorf, Germany; (T.T.R.); (C.N.)
| | - Marco Herling
- Department I of Internal Medicine, University Hospital of Cologne, 50937 Cologne, Germany; (M.H.)
- Department of Hematology, Cellular Therapy and Hemostaseology, University of Leipzig, 04103 Leipzig, Germany
| | - Bianca Bulimaga
- Institute of Pathology, University Hospital of Cologne, 50937 Cologne, Germany; (J.N.G.); (Y.S.); (X.Y.); (H.E.-S.); (B.B.); (R.B.)
- Center for Molecular Medicine Cologne, University of Cologne, 50937 Cologne, Germany;
| | - Elena Vasyutina
- Department I of Internal Medicine, University Hospital of Cologne, 50937 Cologne, Germany; (M.H.)
- Department of Hematology, Cellular Therapy and Hemostaseology, University of Leipzig, 04103 Leipzig, Germany
| | - Michal R. Schweiger
- Center for Molecular Medicine Cologne, University of Cologne, 50937 Cologne, Germany;
- Institute for Epigenetics, University Hospital of Cologne, 50937 Cologne, Germany
| | - Reinhard Büttner
- Institute of Pathology, University Hospital of Cologne, 50937 Cologne, Germany; (J.N.G.); (Y.S.); (X.Y.); (H.E.-S.); (B.B.); (R.B.)
- Center for Molecular Medicine Cologne, University of Cologne, 50937 Cologne, Germany;
| | - Margarete Odenthal
- Institute of Pathology, University Hospital of Cologne, 50937 Cologne, Germany; (J.N.G.); (Y.S.); (X.Y.); (H.E.-S.); (B.B.); (R.B.)
- Center for Molecular Medicine Cologne, University of Cologne, 50937 Cologne, Germany;
| | - Maria M. Anokhina
- Institute of Pathology, University Hospital of Cologne, 50937 Cologne, Germany; (J.N.G.); (Y.S.); (X.Y.); (H.E.-S.); (B.B.); (R.B.)
- Center for Molecular Medicine Cologne, University of Cologne, 50937 Cologne, Germany;
- Institute of Pathology, University Hospital of Duesseldorf, 40225 Duesseldorf, Germany; (T.T.R.); (C.N.)
| |
Collapse
|
3
|
Rubio K, Romero-Olmedo AJ, Sarvari P, Swaminathan G, Ranvir VP, Rogel-Ayala DG, Cordero J, Günther S, Mehta A, Bassaly B, Braubach P, Wygrecka M, Gattenlöhner S, Tresch A, Braun T, Dobreva G, Rivera MN, Singh I, Graumann J, Barreto G. Non-canonical integrin signaling activates EGFR and RAS-MAPK-ERK signaling in small cell lung cancer. Theranostics 2023; 13:2384-2407. [PMID: 37215577 PMCID: PMC10196829 DOI: 10.7150/thno.79493] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2022] [Accepted: 03/25/2023] [Indexed: 05/24/2023] Open
Abstract
Background: Small cell lung cancer (SCLC) is an extremely aggressive cancer type with a patient median survival of 6-12 months. Epidermal growth factor (EGF) signaling plays an important role in triggering SCLC. In addition, growth factor-dependent signals and alpha-, beta-integrin (ITGA, ITGB) heterodimer receptors functionally cooperate and integrate their signaling pathways. However, the precise role of integrins in EGF receptor (EGFR) activation in SCLC remains elusive. Methods: We analyzed human precision-cut lung slices (hPCLS), retrospectively collected human lung tissue samples and cell lines by classical methods of molecular biology and biochemistry. In addition, we performed RNA-sequencing-based transcriptomic analysis in human lung cancer cells and human lung tissue samples, as well as high-resolution mass spectrometric analysis of the protein cargo from extracellular vesicles (EVs) that were isolated from human lung cancer cells. Results: Our results demonstrate that non-canonical ITGB2 signaling activates EGFR and RAS/MAPK/ERK signaling in SCLC. Further, we identified a novel SCLC gene expression signature consisting of 93 transcripts that were induced by ITGB2, which may be used for stratification of SCLC patients and prognosis prediction of LC patients. We also found a cell-cell communication mechanism based on EVs containing ITGB2, which were secreted by SCLC cells and induced in control human lung tissue RAS/MAPK/ERK signaling and SCLC markers. Conclusions: We uncovered a mechanism of ITGB2-mediated EGFR activation in SCLC that explains EGFR-inhibitor resistance independently of EGFR mutations, suggesting the development of therapies targeting ITGB2 for patients with this extremely aggressive lung cancer type.
Collapse
Affiliation(s)
- Karla Rubio
- Université de Lorraine, CNRS, Laboratoire IMoPA, UMR 7365; F-54000 Nancy, France
- Lung Cancer Epigenetics, Max-Planck-Institute for Heart and Lung Research; 61231 Bad Nauheim, Germany
- Department of Pathology, Massachusetts General Hospital and Harvard Medical School; Charlestown, MA, 02129, USA
- International Laboratory EPIGEN, Consejo de Ciencia y Tecnología del Estado de Puebla (CONCYTEP), Instituto de Ciencias, EcoCampus, Benemérita Universidad Autónoma de Puebla; Puebla 72570, Mexico
| | - Addi J. Romero-Olmedo
- Lung Cancer Epigenetics, Max-Planck-Institute for Heart and Lung Research; 61231 Bad Nauheim, Germany
- Institute of Medical Microbiology and Hospital Hygiene, Department of Medicine, Philipps-University Marburg; Marburg, Germany
| | - Pouya Sarvari
- Independent Researcher, collaborator of International Laboratory EPIGEN-CONCYTEP
| | | | - Vikas P. Ranvir
- Emmy Noether Research Group Epigenetic Machineries and Cancer, Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
| | - Diana G. Rogel-Ayala
- Université de Lorraine, CNRS, Laboratoire IMoPA, UMR 7365; F-54000 Nancy, France
- Lung Cancer Epigenetics, Max-Planck-Institute for Heart and Lung Research; 61231 Bad Nauheim, Germany
| | - Julio Cordero
- Department of Cardiovascular Genomics and Epigenomics, European Center for Angioscience (ECAS), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
- German Centre for Cardiovascular Research (DZHK)
| | - Stefan Günther
- ECCPS Bioinformatics and Deep Sequencing Platform, Max-Planck-Institute for Heart and Lung Research; 61231 Bad Nauheim, Germany
- Department of Cardiac Development, Max-Planck-Institute for Heart and Lung Research; 61231 Bad Nauheim, Germany
| | - Aditi Mehta
- Lung Cancer Epigenetics, Max-Planck-Institute for Heart and Lung Research; 61231 Bad Nauheim, Germany
- Pharmaceutical Technology and Biopharmaceutics, Department of Pharmacy, Ludwig-Maximilians-University of Munich; Munich, Germany
| | - Birgit Bassaly
- Institute for Pathology, Justus Liebig University; 35392 Gießen, Germany
| | - Peter Braubach
- Institute for Pathology, Hannover Medical School; Hanover, Germany
- Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH) Research Network; Hanover, Germany
| | - Malgorzata Wygrecka
- Center for Infection and Genomics of the Lung (CIGL), Universities of Giessen and Marburg Lung Center; Giessen, Germany
- Institute of Lung Health, German Center for Lung Research (DZL); Giessen, Germany
| | | | - Achim Tresch
- CECAD, University of Cologne; Cologne, Germany
- Faculty of Medicine and University Hospital, University of Cologne; Cologne, Germany
- Center for Data and Simulation Science, University of Cologne; Cologne, Germany
| | - Thomas Braun
- Department of Cardiac Development, Max-Planck-Institute for Heart and Lung Research; 61231 Bad Nauheim, Germany
| | - Gergana Dobreva
- Department of Cardiovascular Genomics and Epigenomics, European Center for Angioscience (ECAS), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
- German Centre for Cardiovascular Research (DZHK)
| | - Miguel N. Rivera
- Department of Pathology, Massachusetts General Hospital and Harvard Medical School; Charlestown, MA, 02129, USA
- Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School; Charlestown, MA, 02129, USA
| | - Indrabahadur Singh
- Emmy Noether Research Group Epigenetic Machineries and Cancer, Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
| | - Johannes Graumann
- Biomolecular Mass Spectrometry, Max-Planck-Institute for Heart and Lung Research; 61231 Bad Nauheim, Germany
- Institute of Translational Proteomics, Department of Medicine, Philipps-University Marburg; 35043 Marburg, Germany
| | - Guillermo Barreto
- Université de Lorraine, CNRS, Laboratoire IMoPA, UMR 7365; F-54000 Nancy, France
- Lung Cancer Epigenetics, Max-Planck-Institute for Heart and Lung Research; 61231 Bad Nauheim, Germany
- International Laboratory EPIGEN, Consejo de Ciencia y Tecnología del Estado de Puebla (CONCYTEP), Instituto de Ciencias, EcoCampus, Benemérita Universidad Autónoma de Puebla; Puebla 72570, Mexico
| |
Collapse
|
4
|
Qin TT, Li ZH, Li LX, Du K, Yang JG, Zhang ZQ, Wu XX, Ma JL. Sanguinarine, identified as a natural alkaloid LSD1 inhibitor, suppresses lung cancer cell growth and migration. IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES 2022; 25:781-788. [PMID: 35949313 PMCID: PMC9320206 DOI: 10.22038/ijbms.2022.62541.13851] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/31/2021] [Accepted: 05/28/2022] [Indexed: 11/21/2022]
Abstract
Objectives Lysine-specific demethylase1 (LSD1), an important class of histone demethylases, plays a crucial role in regulation of mammalian biology. The up-regulated LSD1 expression was frequently associated with progress and oncogenesis of multiple human cancers, including non-small cell lung cancer (NSCLC). Therefore, inhibition of LSD1 may provide an attractive strategy for cancer treatment. We investigated the effect of sanguinarine against lung cancer cells as a natural alkaloid LSD1 inhibitor. Materials and Methods The inhibition properties of sanguinarine to the recombinant LSD1 were evaluated by a fluorescence-based method. Subsequently, assays such as viability, apoptosis, clonogenicity, wound healing, and transwell were performed on H1299 and H1975 cells after treatment with sanguinarine. Results Upon screening our in-house natural chemical library toward LSD1, we found that sanguinarine possessed a potent inhibitory effect against LSD1 with the IC50 value of 0.4 μM in a reversible manner. Molecular docking simulation suggested that sanguinarine may inactivate LSD1 by inserting into the binding pocket of LSD1 to compete with the FAD site. In H1299 and H1975 cells, sanguinarine inhibited the demethylation of LSD1, validating its cellular activity against the enzyme. Further studies showed that sanguinarine exhibited a strong capacity to suppress colony formation, inhibit migration and invasion, as well as induce apoptosis of H1299 and H1975 cells. Conclusion Our findings present a new chemical scaffold for LSD1 inhibitors, and also provide new insight into the anti-NSCLC action of sanguinarine.
Collapse
Affiliation(s)
- Ting-ting Qin
- Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou 450046, Henan Province, China
| | - Zhong-hua Li
- Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou 450046, Henan Province, China
| | - Li-xin Li
- Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou 450046, Henan Province, China
| | - Kun Du
- School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou 450046, Henan province, China
| | - Ji-ge Yang
- Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou 450046, Henan Province, China
| | - Zhen-qiang Zhang
- Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou 450046, Henan Province, China
| | - Xiang-xiang Wu
- Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou 450046, Henan Province, China ,Corresponding authors: Xiang-xiang Wu. Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou 450046, Henan Province, China. ; Jin-lian Ma. Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou 450046, Henan Province, China.
| | - Jin-lian Ma
- Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou 450046, Henan Province, China ,Corresponding authors: Xiang-xiang Wu. Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou 450046, Henan Province, China. ; Jin-lian Ma. Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou 450046, Henan Province, China.
| |
Collapse
|
5
|
Hong Y, Li X, Zhu J. LSD1-mediated stabilization of SEPT6 protein activates the TGF-β1 pathway and regulates non-small-cell lung cancer metastasis. Cancer Gene Ther 2021; 29:189-201. [PMID: 33664458 DOI: 10.1038/s41417-021-00297-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2020] [Revised: 12/30/2020] [Accepted: 01/13/2021] [Indexed: 01/21/2023]
Abstract
Non-small cell lung cancer (NSCLC) is a prevalent cancer with unfavorable prognosis. Over the past decade accumulating studies have reported an involvement of lysine-specific histone demethylase 1 (LSD1) in NSCLC development. Here, we aimed to explore whether LSD1 affects the metastasis of NSCLC by mediating Septin 6 (SEPT6) through the TGF-β1 pathway. RT-qPCR was used to determine LSD1 and SEPT6 expression in NSCLC tissues and cells. Interactions between LSD1, SEPT6, and TGF-β1 were detected using lentivirus-mediated silencing of LSD1 and overexpression of SEPT6. The role of LSD1 and SEPT6 in mediating the biological behavior of NSCLC cells was determined using the EdU proliferation assay, Transwell assay, and flow cytometry. Thereafter, transplanted cell tumors into nude mice were used to explore the in vivo effects of LSD1 and SEPT6 on metastasis of NSCLC. LSD1 and SEPT6 were overexpressed in NSCLC tissue and cell samples. LSD1 could demethylate the promoter of the SEPT6 to positively regulate SEPT6 expression. LSD1 promoted proliferation, migration, and invasion, while suppressing the apoptosis of NSCLC cells by increasing SEPT6 expression. LSD1-mediated SEPT6 accelerated in vivo NSCLC metastasis through the TGF-β1/Smad pathway. Collectively, LSD1 demethylates SEPT6 promoter to upregulate SEPT6, which activates TGF-β1 pathway, thereby promoting metastasis of NSCLC.
Collapse
Affiliation(s)
- Yanni Hong
- Department of Oncology, Quanzhou First Hospital Affiliated Fujian Medical University, Quanzhou, P.R. China.
| | - Xiaofeng Li
- Department of Oncology, Quanzhou First Hospital Affiliated Fujian Medical University, Quanzhou, P.R. China
| | - Jinfeng Zhu
- Department of Oncology, Quanzhou First Hospital Affiliated Fujian Medical University, Quanzhou, P.R. China
| |
Collapse
|
6
|
Sun P, Sun L, Cui J, Liu L, He Q. Long noncoding RNA HAS2-AS1 accelerates non-small cell lung cancer chemotherapy resistance by targeting LSD1/EphB3 pathway. Am J Transl Res 2020; 12:950-958. [PMID: 32269726 PMCID: PMC7137060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2019] [Accepted: 01/02/2020] [Indexed: 06/11/2023]
Abstract
The essential roles of long noncoding RNA (lncRNA) have been identified by emerging literature in the non-small cell lung cancer (NSCLC). However, the role of lncRNA hyaluronan synthase 2 antisense 1 (HAS2-AS1) in the NSCLC tumorigenesis is not clear. Here, we investigate the role and mechanism of HAS2-AS1 in the NSCLC tumorigenesis. In the NSCLC tissue and cells, HAS2-AS1 was found to be up-regulated, which, in turn, indicated the poor prognosis of NSCLC patients. Functional experiments illustrated that HAS2-AS1 promoted the proliferation, invasion and gefitinib chemotherapy resistance of NSCLC cells. In vivo, HAS2-AS1 knockdown suppressed the tumor growth. Mechanically, HAS2-AS1 recruited the lysine-specific demethylase 1 (LSD1) to the EphB3 promoter region to inhibit its transcription. In conclusion, this finding elucidates the essential roles of HAS2-AS1 in the NSCLC tumorigenesis, providing a possible treatment strategy for the NSCLC.
Collapse
Affiliation(s)
- Peng Sun
- Department of Oncology, The Second Hospital of Dalian Medical University Dalian, China
| | - Limin Sun
- Department of Oncology, The Second Hospital of Dalian Medical University Dalian, China
| | - Jia Cui
- Department of Oncology, The Second Hospital of Dalian Medical University Dalian, China
| | - Lili Liu
- Department of Oncology, The Second Hospital of Dalian Medical University Dalian, China
| | - Qing He
- Department of Oncology, The Second Hospital of Dalian Medical University Dalian, China
| |
Collapse
|
7
|
Dalvi PS, Macheleidt IF, Lim SY, Meemboor S, Müller M, Eischeid-Scholz H, Schaefer SC, Buettner R, Klein S, Odenthal M. LSD1 Inhibition Attenuates Tumor Growth by Disrupting PLK1 Mitotic Pathway. Mol Cancer Res 2019; 17:1326-1337. [PMID: 30760542 DOI: 10.1158/1541-7786.mcr-18-0971] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2018] [Revised: 01/16/2019] [Accepted: 02/08/2019] [Indexed: 11/16/2022]
Abstract
Lysine-specific demethylase 1 (LSD1) is a histone modifier that is highly overexpressed in lung adenocarcinoma, which results in aggressive tumor biology. Tumor cell proliferation and migration analysis after LSD1 inhibition in the lung adenocarcinoma cell line PC9, using the LSD1 inhibitor HCI-2509 and siRNA, demonstrated that LSD1 activity was essential for proliferation and migration capacities of tumor cells. Moreover, reduced proliferation rates after LSD1 inhibition were shown to be associated with a cell-cycle arrest of the tumor cells in the G2-M-phase. Expression profiling followed by functional classification and pathway analysis indicated prominent repression of the polo-like kinase 1 (PLK1) pathway upon LSD1 inhibition. In contrast, transient overexpression of exogenous PLK1 plasmid rescued the LSD1 inhibition-mediated downregulation of PLK1 pathway genes. Mechanistically, LSD1 directly regulates expression of PLK1 by binding to its promoter region that subsequently affects expression of its downstream target genes. Notably, using lung adenocarcinoma TCGA datasets a significant correlation between LSD1 and PLK1 along with its downstream targets was observed. Furthermore, the LSD1/PLK1 linkage was confirmed by IHC analysis in a clinical lung adenocarcinoma cohort (n = 43). Conclusively, this is the first study showing a direct transcriptional link between LSD1 and PLK1. IMPLICATIONS: These findings point to a role of LSD1 in regulating PLK1 and thus efficient G2-M-transition-mediating proliferation of tumor cells and suggest targeting the LSD1/PLK1 axis as a novel therapeutic approach for lung adenocarcinoma treatment.
Collapse
Affiliation(s)
- Priya S Dalvi
- Institute of Pathology, University Hospital of Cologne, Cologne, Germany
- Center for Molecular Medicine Cologne, Cologne, Germany
| | - Iris F Macheleidt
- Institute of Pathology, University Hospital of Cologne, Cologne, Germany
- Center for Molecular Medicine Cologne, Cologne, Germany
| | - So-Young Lim
- Institute of Pathology, University Hospital of Cologne, Cologne, Germany
- Center for Molecular Medicine Cologne, Cologne, Germany
| | - Sonja Meemboor
- Institute of Pathology, University Hospital of Cologne, Cologne, Germany
- Center for Molecular Medicine Cologne, Cologne, Germany
| | - Marion Müller
- Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | | | - Stephan C Schaefer
- Institute of Pathology, University Hospital of Cologne, Cologne, Germany
- Center for Integrated Oncology Cologne Bonn, Cologne, Germany
- Lung Cancer Group Cologne, University Hospital of Cologne, Cologne, Germany
| | - Reinhard Buettner
- Institute of Pathology, University Hospital of Cologne, Cologne, Germany
- Center for Molecular Medicine Cologne, Cologne, Germany
- Center for Integrated Oncology Cologne Bonn, Cologne, Germany
- Lung Cancer Group Cologne, University Hospital of Cologne, Cologne, Germany
| | - Sebastian Klein
- Institute of Pathology, University Hospital of Cologne, Cologne, Germany
- Department of Translational Genomics, University of Cologne, Cologne, Germany
- Else Kröner Forschungskolleg Cologne, University Hospital of Cologne, Cologne, Germany
| | - Margarete Odenthal
- Institute of Pathology, University Hospital of Cologne, Cologne, Germany.
- Center for Molecular Medicine Cologne, Cologne, Germany
| |
Collapse
|
8
|
Macheleidt IF, Dalvi PS, Lim SY, Meemboor S, Meder L, Käsgen O, Müller M, Kleemann K, Wang L, Nürnberg P, Rüsseler V, Schäfer SC, Mahabir E, Büttner R, Odenthal M. Preclinical studies reveal that LSD1 inhibition results in tumor growth arrest in lung adenocarcinoma independently of driver mutations. Mol Oncol 2018; 12:1965-1979. [PMID: 30220105 PMCID: PMC6210049 DOI: 10.1002/1878-0261.12382] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2018] [Revised: 08/01/2018] [Accepted: 08/22/2018] [Indexed: 01/18/2023] Open
Abstract
Lung adenocarcinoma (LUAD) is the most prevalent subtype of non-small cell lung cancer. Despite the development of novel targeted and immune therapies, the 5-year survival rate is still only 21%, indicating the need for more efficient treatment regimens. Lysine-specific demethylase 1 (LSD1) is an epigenetic eraser that modifies histone 3 methylation status, and is highly overexpressed in LUAD. Using representative human cell culture systems and two autochthonous transgenic mouse models, we investigated inhibition of LSD1 as a novel therapeutic option for treating LUAD. The reversible LSD1 inhibitor HCI-2509 significantly reduced cell growth with an IC50 of 0.3-5 μmin vitro, which was linked to an enhancement of histone 3 lysine methylation. Most importantly, growth arrest, as well as inhibition of the invasion capacities, was independent of the underlying driver mutations. Subsequent expression profiling revealed that the cell cycle and replication machinery were prominently affected after LSD1 inhibition. In addition, our data provide evidence that LSD1 blockade significantly interferes with EGFR downstream signaling. Finally, our in vitro results were confirmed by preclinical therapeutic approaches, including the use of two autochthonous transgenic LUAD mouse models driven by either EGFR or KRAS mutations. Importantly, LSD1 inhibition resulted in significantly lower tumor formation and a strong reduction in tumor progression, which were independent of the underlying mutational background of the mouse models. Hence, our findings provide substantial evidence indicating that tumor growth of LUAD can be markedly decreased by HCI-2509 treatment, suggesting its use as a single agent maintenance therapy or combined therapeutical application in novel concerted drug approaches.
Collapse
Affiliation(s)
- Iris F Macheleidt
- Institute for Pathology, University Hospital of Cologne, Germany.,Center for Molecular Medicine, University of Cologne, Germany
| | - Priya S Dalvi
- Institute for Pathology, University Hospital of Cologne, Germany.,Center for Molecular Medicine, University of Cologne, Germany
| | - So-Young Lim
- Institute for Pathology, University Hospital of Cologne, Germany.,Center for Molecular Medicine, University of Cologne, Germany
| | - Sonja Meemboor
- Institute for Pathology, University Hospital of Cologne, Germany.,Center for Molecular Medicine, University of Cologne, Germany
| | - Lydia Meder
- Center for Molecular Medicine, University of Cologne, Germany.,Department I of Internal Medicine, University Hospital of Cologne, Germany
| | - Olivia Käsgen
- Institute for Pathology, University Hospital of Cologne, Germany.,Center for Molecular Medicine, University of Cologne, Germany
| | - Marion Müller
- Institute for Pathology, University Hospital of Cologne, Germany
| | - Karolin Kleemann
- Institute for Pathology, University Hospital of Cologne, Germany.,Center for Molecular Medicine, University of Cologne, Germany
| | - Lingyu Wang
- Institute for Pathology, University Hospital of Cologne, Germany.,Center for Molecular Medicine, University of Cologne, Germany
| | - Peter Nürnberg
- Cologne Center for Genomics, University of Cologne, Germany
| | - Vanessa Rüsseler
- Institute for Pathology, University Hospital of Cologne, Germany.,Lung Cancer Group Cologne, University Hospital of Cologne, Germany
| | - Stephan C Schäfer
- Institute for Pathology, University Hospital of Cologne, Germany.,Lung Cancer Group Cologne, University Hospital of Cologne, Germany.,Center for Integrative Oncology, University Clinic of Cologne and Bonn, Germany
| | - Esther Mahabir
- Comparative Medicine, Center for Molecular Medicine, University of Cologne, Germany
| | - Reinhard Büttner
- Institute for Pathology, University Hospital of Cologne, Germany.,Center for Molecular Medicine, University of Cologne, Germany.,Lung Cancer Group Cologne, University Hospital of Cologne, Germany.,Center for Integrative Oncology, University Clinic of Cologne and Bonn, Germany
| | - Margarete Odenthal
- Institute for Pathology, University Hospital of Cologne, Germany.,Center for Molecular Medicine, University of Cologne, Germany.,Lung Cancer Group Cologne, University Hospital of Cologne, Germany
| |
Collapse
|
9
|
Chen Y, Liu X, Li Y, Quan C, Zheng L, Huang K. Lung Cancer Therapy Targeting Histone Methylation: Opportunities and Challenges. Comput Struct Biotechnol J 2018; 16:211-223. [PMID: 30002791 PMCID: PMC6039709 DOI: 10.1016/j.csbj.2018.06.001] [Citation(s) in RCA: 39] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2018] [Revised: 06/10/2018] [Accepted: 06/11/2018] [Indexed: 12/18/2022] Open
Abstract
Lung cancer is one of the most common malignancies. In spite of the progress made in past decades, further studies to improve current therapy for lung cancer are required. Dynamically controlled by methyltransferases and demethylases, methylation of lysine and arginine residues on histone proteins regulates chromatin organization and thereby gene transcription. Aberrant alterations of histone methylation have been demonstrated to be associated with the progress of multiple cancers including lung cancer. Inhibitors of methyltransferases and demethylases have exhibited anti-tumor activities in lung cancer, and multiple lead candidates are under clinical trials. Here, we summarize how histone methylation functions in lung cancer, highlighting most recent progresses in small molecular inhibitors for lung cancer treatment.
Collapse
Key Words
- ALK, anaplastic lymphoma kinase
- DUSP3, dual-specificity phosphatase 3
- EMT, epithelial-to-mesenchymal transition
- Elk1, ETS-domain containing protein
- HDAC, histone deacetylase
- Histone demethylase
- Histone demethylation
- Histone methylation
- Histone methyltransferase
- IHC, immunohistochemistry
- Inhibitors
- KDMs, lysine demethylases
- KLF2, Kruppel-like factor 2
- KMTs, lysine methyltransferases
- LSDs, lysine specific demethylases
- Lung cancer
- MEP50, methylosome protein 50
- NSCLC, non-small cell lung cancer
- PAD4, peptidylarginine deiminase 4
- PCNA, proliferating cell nuclear antigen
- PDX, patient-derived xenografts
- PRC2, polycomb repressive complex 2
- PRMTs, protein arginine methyltrasferases
- PTMs, posttranslational modifications
- SAH, S-adenosyl-L-homocysteine
- SAM, S-adenosyl-L-methionine
- SCLC, small cell lung cancer
- TIMP3, tissue inhibitor of metalloproteinase 3
Collapse
Affiliation(s)
- Yuchen Chen
- Tongji School of Pharmacy, Tongji Medical College, Huazhong University of Science & Technology, Wuhan 430030, China
| | - Xinran Liu
- Tongji School of Pharmacy, Tongji Medical College, Huazhong University of Science & Technology, Wuhan 430030, China
| | - Yangkai Li
- Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan 430030, China
| | - Chuntao Quan
- Tongji School of Pharmacy, Tongji Medical College, Huazhong University of Science & Technology, Wuhan 430030, China
| | - Ling Zheng
- College of Life Sciences, Wuhan University, Wuhan 430072, China
| | - Kun Huang
- Tongji School of Pharmacy, Tongji Medical College, Huazhong University of Science & Technology, Wuhan 430030, China
| |
Collapse
|